European Union

Mon810 maize is the only transgenic GM plant authorized for commercial cultivation in the European Union. This authorization was initially granted, via France, almost 30 years ago, in 1998, for an initial period of 10 years. A renewal application was submitted in 2007. Since then, no decision has been taken by the European authorities. How this maize, which authorization theoretically expired in 2008, can still be grown legally in Europe? Simply because European law accepts that, as long as the European Commission has not responded to a request for renewal, the initial authorization remains valid. To date, it’s been 15 years that the Commission fails to respond to Bayer/Monsanto’s request.

In less than a year and a half, from May 3, 2022 to October 12, 2023, the previous European Commission has launched a number of legislative initiatives concerning the Living. The deregulation of GMOs, the digitization of living organisms and even patents are just some of the issues on the table of member states and the European Parliament. If adopted, these projects will make it easier for companies with substantial financial, human and technical resources to take ownership of the Living. These initiatives do echo current international negotiations.

Between 1 January 2021 and the present day, the European Union has had to deal with almost fifty cases of the illegal presence of GMOs on its territory. Most of the cases reported by the national authorities involve GMO plants originating in Asian countries such as Vietnam and Thailand, but also in other countries such as Ukraine, the United States and, more surprisingly, France… GMO micro-organisms have also been detected in batches of food additives used in human and animal nutrition.

For the past fifteen years, governments have been discussing “synthetic biology” on an international level. If to date, an “operational” definition exists, the outlines of this field remain hard to draw. Are talks of “synthetic biology” simply a change of semantics, or a genuinely new frontier of the biotechnology field? For the moment, examples of organisms or molecules obtained by synthetic biology are accumulating: unnatural proteins, GMO plants, GMO bacteria, recreated viruses, modification of living organisms directly in the environment, GMO insects, xenobacteria…

Toulouse-based Micropep Technologies has just had one of its fungicidal micropeptides approved in the United States. The technology, developed and patented by this CNRS spin-off, is aiming for European approval by 2030. However, these micropeptides are raising questions about their potential impact on ecosystems.

During the parliamentary work on the proposal for a European regulation on plant reproductive material, known as the “seeds regulation”, a question arose: should so-called “non-targeted mutagenesis” be considered as an “essentially biological process”? As these processes are excluded from patentability, the question may seem important. But such a decision would not be without consequences for the regulation of GMOs.

The European Commission’s proposal to deregulate GMOs made in 2023 will not have come to an end before the European elections, as its promoters had hoped. However, beside the fact that this proposal is not the only file concerning GMOs, the forthcoming period of suspension of European parliamentary work could be used for bilateral discussions.

While the European Union has been discussing GMO deregulation since July 2023, European and French scientific experts have been and continue to be quite ignored. In France, although the opinion of the Anses was required as early as 2021, its publication took place in March 2024, a month after the vote by MEPs. The latter decided to consult their european experts after the vote, rather than before. However, in order to deliver its opinion in July 2024, the EFSA will make an exception to its procedure: it will not organize a public consultation…